Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Stocks Generating Improved Relative Strength: Protagonist Therapeutics

The Relative Strength (RS) Rating for Protagonist Therapeutics moved up into a higher percentile Thursday, as it got a lift from 70 to 73.

This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history reveals that the best stocks often have an 80 or higher RS Rating as they begin their largest climbs. See if Protagonist Therapeutics can continue to rebound and hit that benchmark.

Can You Really Time The Stock Market?

Protagonist Therapeutics is trying to complete a consolidation with a 48.89 buy point. See if it can break out in heavy trade.

Protagonist Therapeutics showed 0% EPS growth in its most recent report. Sales increased -100%. Look for the next report on or around Mar. 18.

Protagonist Therapeutics earns the No. 17 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Jazz Pharmaceuticals and Novartis ADR are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.